Effects of mirabegron on JJ stent-related symptoms: A multicentric study

Simple item page
dc.contributor.authorCinar O.
dc.contributor.authorTanidir Y.
dc.contributor.authorOzer S.
dc.contributor.authorCizmeci S.
dc.contributor.authorErbatu O.
dc.contributor.authorOzdemir T.
dc.contributor.authorGirgin R.
dc.contributor.authorOngun S.
dc.contributor.authorUcer O.
dc.contributor.authorKizilay F.
dc.contributor.authorSen V.
dc.contributor.authorIrer B.
dc.contributor.authorBozkurt O.
dc.date.accessioned2024-07-22T08:06:11Z
dc.date.available2024-07-22T08:06:11Z
dc.date.issued2021
dc.description.abstractAims of the study: To investigate the effect of mirabegron 50 mg/daily for JJ stent-related symptoms after ureteroscopic stone surgery. Methods: Medical records of 145 patients who were given a single daily oral dose of 50 mg of mirabegron for relieving stent-related symptoms were retrospectively analysed. Demographic and clinical data and stone parameters were recorded. All participants completed the Turkish version of the Ureter Symptom Score Questionnaire (USSQ-T) on the postoperative 7th day, and again after at least 3 weeks, before JJ stent removal. The severity of stent-related symptoms was statistically compared before and after the mirabegron treatment. Results: The mean urinary symptoms score decreased significantly from 30.87 ± 9.43 to 22.61 ± 6.78 (P <.0001), mean body pain score decreased significantly from 21.82 ± 11.22 to 14.03 ± 7.52 (P <.0001), mean work performance score decreased from 10.50 ± 8.61 to 7.02 ± 6.51 (P <.0001) and mean general health score decreased significantly from 15.43 ± 6.50 to 11.12 ± 3.70 (P <.0001). The mean sexual matters score significantly decreased from 3.88 ± 3.40 to 2.48 ± 2.03 (P <.0001), the additional problem score decreased from 9.31 ± 4.61 to 6.51 ± 2.83 (P <.0001) and the overall quality of life (QoL) score decreased from 5.18 ± 1.94 to 4.23 ± 1.71 after mirabegron use (P <.0001). Conclusion: Daily use of 50 g of mirabegron significantly improved stent-related symptoms, sexual matters and quality of life. © 2020 John Wiley & Sons Ltd
dc.identifier.DOI-ID10.1111/ijcp.13857
dc.identifier.issn13685031
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13417
dc.language.isoEnglish
dc.publisherBlackwell Publishing Ltd
dc.rightsAll Open Access; Gold Open Access
dc.subjectAcetanilides
dc.subjectHumans
dc.subjectQuality of Life
dc.subjectRetrospective Studies
dc.subjectStents
dc.subjectSurveys and Questionnaires
dc.subjectThiazoles
dc.subjectUreter
dc.subjectmirabegron
dc.subjectacetanilide derivative
dc.subjectmirabegron
dc.subjectthiazole derivative
dc.subjectadult
dc.subjectArticle
dc.subjectdemography
dc.subjectdevice removal
dc.subjectdrug effect
dc.subjectdrug use
dc.subjectfemale
dc.subjecthuman
dc.subjectjob performance
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmiddle aged
dc.subjectpostoperative period
dc.subjectpriority journal
dc.subjectquality of life
dc.subjectquestionnaire
dc.subjectretrospective study
dc.subjectscoring system
dc.subjectsingle drug dose
dc.subjectureter stone
dc.subjectureter surgery
dc.subjectureteroscopy
dc.subjectadverse device effect
dc.subjectclinical trial
dc.subjectmulticenter study
dc.subjectquality of life
dc.subjectstent
dc.subjectureter
dc.titleEffects of mirabegron on JJ stent-related symptoms: A multicentric study
dc.typeArticle

Files

Collections

Scopus Koleksiyonu